Baum’s Insider Buy Signals Confidence in Harrow’s Near‑Term Rally Despite Volatility

Insider Buying Spikes Amid a Volatile Quarter

On May 14, 2026, Mark Baum, the Chief Executive Officer of Harrow, completed a purchase of 10,000 shares of the company’s common stock at a weighted‑average price of $30.20 per share. This transaction increased Baum’s total holdings to 2,996,130 shares, representing a 1 % rise from his prior position. The acquisition is noteworthy in the context of a turbulent trading week, during which Harrow’s shares have fallen 19 % and 20 % over the past month, respectively, and the company’s price‑to‑earnings ratio remains negative, compounded by an 8‑point loss in the most recent quarter.

Investor Takeaway

Baum’s decision to buy at a depressed price level signals a conviction that the share price is temporarily undervalued. Harrow’s ongoing revenue trajectory for its flagship products VEVYE® and IHEEZO®, coupled with reaffirmed guidance, suggests that the purchase may be a bet on a near‑term rebound. Nevertheless, the trade also highlights the inherent risk that management’s equity exposure remains tied to a stock that has struggled to maintain positive earnings. Investors should therefore examine Harrow’s cash runway, R&D pipeline, and the sustainability of its commercial expansion, all of which could materially influence the stock’s valuation trajectory.

Pattern of Confidence in Baum’s Trading Footprint

A review of Baum’s historical insider activity reveals a consistent pattern of acquiring shares at low valuations and occasionally liquidating positions when the price spikes. In December 2025, Baum purchased 180,000 shares at $3.95 and subsequently sold 79,994 shares at $47.06—a 20× return achieved within a few weeks. Additionally, Baum has exercised stock options at $0, indicating a willingness to accrue equity exposure even when market conditions are neutral. This blend of opportunistic buying and strategic liquidation illustrates a hands‑on approach to capital management and a readiness to capitalize on short‑term price swings while maintaining a long‑term stake in the company.

Mixed Insider Activity Across the Company

While Baum’s trade appears bullish, other insider transactions paint a more nuanced picture. CFO Andrew Boll purchased 3,500 shares at $29.90, reinforcing confidence from the top executive team. Conversely, the Opaleye Management group has executed a series of sales totaling tens of thousands of shares, and Sullivan Patrick William has sold a large block of 25,000 RSUs. These outflows suggest that certain stakeholders are either diversifying their portfolios or anticipating downside risk. The net effect is a balanced insider sentiment: executive buys counterbalance non‑executive sales.

Implications for Harrow’s Future

Baum’s latest purchase, coupled with Harrow’s solid revenue outlook, could boost investor sentiment, particularly given the high social‑media buzz (108 %) and a positive sentiment score (+71). However, the stock’s negative earnings multiple, recent quarterly losses, and high R&D expense levels mean that any upside will depend on a sustained lift in product sales and successful commercialization. For investors, Baum’s trade should be viewed as a potential catalyst for a short‑term rally, but continuous monitoring of Harrow’s cash flow, pipeline milestones, and broader ophthalmic market dynamics remains essential to assess whether this insider confidence translates into long‑term value creation.

Transaction Summary Table